The world market leader seca turns body composition analysis into a business booster
seca, the German world market leader in medical measuring systems and scales, is expanding its position in the medical fitness industry. Particularly with the measurement of body composition by means of Bioelectrical Impedance Analysis (BIA), seca has a clear advantage in this growing market. The seca medical Body Composition Analyzer (mBCA) is the only BIA device that is fully medically validated (1) and thus offers optimal conditions for personalized training and monitoring programs. At the International Health, Racquet and Sports club Association (IHRSA) 2019 (March 13-16, 2019) in San Diego, California, visitors will learn about potential business models based on this kind of validated...
Validated BIA from seca conforms to consensus on diagnostic methods
The international societies ASPEN, ESPEN, FELANPE and PENSA established the Global Leadership Initiative in Malnutrition (GLIM) to build a worldwide consensus for diagnostic criteria for malnutrition. The consensus report published in September 2018 elevates reduced muscle mass to one of the decisive, independent evaluation criteria used in the diagnosis of malnutrition. seca welcomes this step, which the company sees as validation of its advocacy of improved diagnosis and treatment of malnutrition.
German medical technology company to build on successful projects in viable Benelux markets
Right on the heels of the November opening of the seca | lietuva site, the market leader in medical measuring systems and scales has opened its 16th international subsidiary seca | benelux. The company sees great potential in the progressive healthcare sector in Benelux countries and opportunities for sales, particularly of its EMR-ready and digital measuring solutions.
seca, the global market leader in medical measuring systems and scales, is opening its 15th branch in the Lithuanian capital of Vilnius. With the establishment of the first site dedicated to development only, seca is driving forward its digital transformation from a scale manufacturer to a software and system provider. seca will first hire 10 IT specialists to develop a new software solution that will take seca into new medical business fields. The team is expected to grow to 25 employees by 2021.
"The improvement in body composition is more important than weight loss alone."
On the occasion of World Obesity Day 2018 (October 11th), a current representative survey contracted by seca, the leading manufacturer of medical measuring systems and scales, shows that nearly three-quarters (72%) of respondents (with BMI 30 and higher) have attempted to lose weight, but only 14% have been able to reach their goal and maintain their weight. Reasons for failure included lack of persistence (40%), frustration when success does not come as quickly as desired (39%) and not believing in one's ability to succeed (28%).
Americans do not use knowledge about imminent obesity and obesity continues to increase
Nearly one in two German adults says he has never been weighed at the doctor’s office (47%), but Americans are very well aware of their weight development. In the USA, almost three-quarter (72%) of the patients are weighed at least once a year at the doctor’s office. However, knowledge of negative weight changes and imminent obesity often remains unused, according to a recent survey. It reports the continued presence of barriers to prevention, early diagnosis and treatment of overweight and obesity in the United States.
Quality management satisfies global requirements and secures seca competitive advantages
The German and French quality management systems of seca, the leading manufacturer of medical measuring systems and scales, have been certified according to the revised standards ISO 9001 and ISO 13485 in an audit conducted by TÜV-Süd. In addition, the quality management system at seca headquarters in Hamburg received the Medical Device Single Audit Program (MDSAP) certificate. It shows that seca officially satisfies not only the legal requirements in Europe, but also in the USA, Canada, Australia, Japan and Brazil.